ProBio Grants AbTis Exclusive Global Rights to Discovery-Stage Antibody for Next-Generation ADC

ProBio Inc. entered an exclusive global licensing agreement with AbTis Co., Ltd. covering a discovery-stage therapeutic antibody against an oncology target, the company said in a PR Newswire announcement on November 10, 2026. The agreement includes an upfront payment to ProBio, potential developmental and commercial milestone payments, and royalties on future sales.

How the AbTis Licensing Deal Works

Under the agreement, AbTis receives exclusive global rights to develop and commercialize the antibody asset, which was generated through ProBio's biologics discovery and development capabilities. AbTis is a South Korean biotechnology company and a subsidiary of Dong-A ST that specializes in site-specific conjugation technologies for antibody-drug conjugates.

AbTis plans to build on the antibody asset to expand its pipeline in bispecific antibody-drug conjugates. The company will use its proprietary AbClick site-specific conjugation platform to advance the asset toward development of a next-generation ADC. AbClick is designed to enable controlled, site-specific antibody conjugation, an approach intended to improve the consistency and characteristics of ADCs compared with conventional nonspecific conjugation approaches.

Allen Guo, CEO of ProBio, said: "This agreement demonstrates the value of ProBio's strategy to not only support our partners' programs, but also generate differentiated assets that can advance into innovative therapeutic development." Dr. Hyungsuk Choi, CEO of AbTis, said: "This licensing agreement marks an important step in advancing this promising antibody asset toward ADC development."

ProBio's Manufacturing and Discovery Record

ProBio has supported more than 130 IND approvals across the United States, Europe and Asia-Pacific since 2017, according to akta.pro company records. The same records list more than 90 CMC projects, including more than 30 IND approvals from complex molecules such as proteins and multispecific antibodies, and more than 200 cell line projects for IND filing as of June 2024. ProBio is a subsidiary of GenScript Biotech and was founded in 2020.

Earlier ProBio Partnerships in 2026

In October 2026, ProBio completed a Pre-Approval Inspection by China's NMPA at its Nanjing biologics manufacturing facility, PR Newswire reported. In September 2026, ProBio and Kun Tuo announced a strategic collaboration to provide integrated CDMO-CRO services for advanced therapies in China, according to PR Newswire. In July 2026, ProBio delivered GMP AAV6 materials to UC Irvine and GlyTR Therapeutics for a pan-cancer CAR-T program, achieving about 80% gene insertion versus about 40% with research-grade material, PR Newswire reported.